Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery
- PMID: 31517528
- DOI: 10.4155/fmc-2019-0005
Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery
Abstract
Allosteric modulators of cannabinoid receptors hold great therapeutic potential, as they do not possess intrinsic efficacy, but instead enhance or diminish the receptor's response of orthosteric ligands allowing for the tempering of cannabinoid receptor signaling without the desensitization, tolerance and dependence. Allosteric modulators of cannabinoid receptors have numerous advantages over the orthosteric ligands such as higher receptor type selectivity, probe dependence and biased signaling, so they have a great potential to separate the therapeutic benefits from side effects own of orthosteric ligands. This review aims to give an overview of the CB1 and CB2 receptor allosteric modulators highlighting the structure-activity relationship and pharmacological profile of each classes, and their future promise.
Keywords: allosteric modulator; biased signaling; cannabinoid CB1 receptor; cannabinoid CB2 receptor; drug discovery; endocannabinoid system; probe dependence.
Similar articles
-
Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.Br J Pharmacol. 2019 May;176(10):1455-1469. doi: 10.1111/bph.14440. Epub 2018 Aug 10. Br J Pharmacol. 2019. PMID: 29981240 Free PMC article.
-
The future of type 1 cannabinoid receptor allosteric ligands.Drug Metab Rev. 2018 Feb;50(1):14-25. doi: 10.1080/03602532.2018.1428341. Epub 2018 Jan 21. Drug Metab Rev. 2018. PMID: 29355038
-
Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.ACS Chem Neurosci. 2016 Jun 15;7(6):776-98. doi: 10.1021/acschemneuro.6b00041. Epub 2016 Apr 25. ACS Chem Neurosci. 2016. PMID: 27046127 Free PMC article.
-
Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.Drug Metab Rev. 2018 Feb;50(1):3-13. doi: 10.1080/03602532.2018.1428342. Epub 2018 Jan 21. Drug Metab Rev. 2018. PMID: 29355030 Free PMC article. Review.
-
Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor.Acta Pharmacol Sin. 2019 Mar;40(3):324-335. doi: 10.1038/s41401-018-0164-x. Epub 2018 Oct 17. Acta Pharmacol Sin. 2019. PMID: 30333554 Free PMC article. Review.
Cited by
-
Should oncologists trust cannabinoids?Front Pharmacol. 2023 Jul 13;14:1211506. doi: 10.3389/fphar.2023.1211506. eCollection 2023. Front Pharmacol. 2023. PMID: 37521486 Free PMC article. Review.
-
Cannabinoids as Prospective Anti-Cancer Drugs: Mechanism of Action in Healthy and Cancer Cells.Adv Exp Med Biol. 2023;1410:145-169. doi: 10.1007/5584_2022_748. Adv Exp Med Biol. 2023. PMID: 36396926
-
Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands.Int J Mol Sci. 2023 Mar 24;24(7):6187. doi: 10.3390/ijms24076187. Int J Mol Sci. 2023. PMID: 37047169 Free PMC article. Review.
-
Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist.Life (Basel). 2020 Dec 8;10(12):333. doi: 10.3390/life10120333. Life (Basel). 2020. PMID: 33302569 Free PMC article.
-
Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products.Int J Mol Sci. 2020 Jul 17;21(14):5064. doi: 10.3390/ijms21145064. Int J Mol Sci. 2020. PMID: 32709050 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
